ICYMI: “Prescription drug prices climb into the stratosphere”

May 20, 2015

May 20, 2015 “Prescription drug prices climb into the stratosphere” Read More

Justifying After the Fact Is Not Justification

Oct 22, 2014

What the study should have asked is whether or not the price Gilead set for the therapy is appropriate for all patients–even asymptomatic patients–and whether or not such a large portion of potential societal value should accrue to one company. Read More

[SF Business Times] Gilead’s $1,000-a-pill hepatitis C drug may make financial sense for prisons

Oct 20, 2014

Pricey new hepatitis C drugs, such as Gilead Sciences Inc.'s Sovaldi, may make financial sense to give to give to prisoners, one of the main groups infected with the liver-damaging virus, according to a team of Stanford University researchers. Read More

[The Morning Consult] The Gilead Effect

Oct 14, 2014

Perhaps no company has done as much as Gilead to propel the issue of high drug prices onto center stage or to lay bare the pharmaceutical industry’s approach to pricing new drugs. Read More

[WSJ] Will ‘Son of Sovaldi’ Cause State Medicaid Programs to Erect High Hurdles?

Oct 13, 2014

How might state Medicaid programs cope with a new and equally expensive hepatitis C treatment from Gilead Sciences. Read More

[MarketWatch] Sovaldi pricing raises debate over drug costs

Oct 1, 2014

With the California-based drug manufacturer Gilead Sciences planning to roll out another hepatitis C medication, academics said Wednesday that policy changes are needed in the costly drug market so the interests of patients, health insurers and pharmaceutical companies align. Read More